Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;8(2):151-160.
doi: 10.21037/tp.2019.04.09.

Pulmonary artery banding in dilative cardiomyopathy of young children: review and protocol based on the current knowledge

Affiliations
Review

Pulmonary artery banding in dilative cardiomyopathy of young children: review and protocol based on the current knowledge

Dietmar Schranz et al. Transl Pediatr. 2019 Apr.

Abstract

Dilated cardiomyopathy (DCM) is a leading cause of cardiac death in children. Current therapeutic strategies are focused on improving symptoms of congestive heart failure (CHF); the potentials of cardiac regeneration especially in infants and young children are neglected in particular when DCM is classified as "end-stage". Heart transplantation (HTx) serves as the only life-saving option, despite is palliative character with limited survival time. Therapeutic alternatives are strongly needed, but already existing though less used; presupposed, that cardiac dysfunction and its treatment are not reduced to the four components of heart rate (rhythm), myocardial contractility, preload and afterload. A paradigm shift in the treatment of pediatric heart failure can be achieved by modifying ventricular afterload with improving contra-lateral ventricular function. Adverse ventricular-ventricular interactions (VVI) have the potential to harness them for therapeutic benefit. Surgical placement of a pulmonary artery banding (PAB) utilized in infants and young children with LV-DCM and preserved RV function are able to improve LV function via VVI; it is hypothesized, that functional recovery can be achieved in almost 80% especially of infants with LV-DCM despite criteria for listing to orthotopic HTx. The review summarizes details of the current perioperative treatment enabling each pediatric heart center to utilize rPAB as a strategy for functional recovery, even in centers without the option for Htx. Of course, future studies are needed to delineate the geometrical, temporal and molecular mechanisms of PA-banding-induced ventricular crosstalk and to examine their potential modulation through mechanical, electrophysiological and pharmacological interventions, but our patients are born, now.

Keywords: Dilative cardiomyopathy; children; congestive heart failure (CHF); pulmonary banding; recovery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Summarizes the pulmonary artery banding (PAB) effects on the right (RV) and left ventricle (LV). (A) Depicts the magnet resonance imaging (MRI) in four-chamber view of an infant with left ventricular dilated cardiomyopathy (LV-DCM); (B) shows functional regeneration of the LV based on the PAB induced ventriculo-ventricular interaction (VVI); the MRI was performed before the PAB induced RV hypertension was unloaded by transcatheter balloon dilation. IVS, interventricular septum; LA, left atrium; MV, mitral valve; TV, tricuspid valve.
Figure 2
Figure 2
Shows the open chest and pericardial approach for performing pulmonary artery banding (PAB); the PAB is already placed, the 21 gauge (arterial) cannula is still in place measuring the RV pressure before and after PAB placement.
Figure 3
Figure 3
Distinctive perioperative treatment.

References

    1. Daubeney PE, Nugent AW, Chondros P, et al. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation 2006;114:2671-8. 10.1161/CIRCULATIONAHA.106.635128 - DOI - PubMed
    1. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:1867-76. 10.1001/jama.296.15.1867 - DOI - PubMed
    1. Patel MD, Mohan J, Schneider C, et al. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. JCI Insight 2017. doi: .10.1172/jci.insight.94382 - DOI - PMC - PubMed
    1. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298:1171-9. 10.1001/jama.298.10.1171 - DOI - PubMed
    1. Roche SL, Redington AN. Right ventricle: wrong targets? Another blow for pharmacotherapy in congenital heart diseases. Circulation 2013;127:314-6. 10.1161/CIRCULATIONAHA.112.155887 - DOI - PubMed